VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

Join VolitionRx’s chief commercial officer Gael Forterre and intensive care specialist and haematology key opinion leader Dr Andrew Retter as they cover:

• sepsis, patient case studies and the challenges in diagnosing, treating and monitoring sepsis;
• the connection between NETosis and sepsis;
• the role of Nu.Q® NETs and its clinical evidence and ongoing clinical study programme; and
• Volition’s commercial strategy.

The panel and Q&A are chaired by Soo Romanoff, managing director of healthcare at Edison Group.

Read our latest report on VolitionRx: Snaring sepsis, with early NETs detection

About VolitionRx
VolitionRx is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition’s research and development activities are centred in Belgium, with an innovation laboratory and office in the US and additional offices in London and Singapore.